Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT02349126
Other study ID # Heparc-2005
Secondary ID
Status Withdrawn
Phase Phase 2
First received January 20, 2015
Last updated August 12, 2015
Start date February 2015
Est. completion date March 2016

Study information

Verified date August 2015
Source Arrowhead Research Corporation
Contact n/a
Is FDA regulated No
Health authority Australia: Department of Health and Ageing Therapeutic Goods AdministrationAustralia: Human Research Ethics Committee
Study type Interventional

Clinical Trial Summary

Patients with chronic HBV infection will receive ARC-520 in combination with entecavir or tenofovir and be evaluated for safety and efficacy.


Description:

This is a single-center, open-label study of ARC-520 in combination with entecavir or tenofovir administered to patients with immune active chronic HBV infection. An iterative trial design is anticipated with potential inclusion of additional cohorts with anticipated enrollment of up to 60 patients. Patients who have signed a Human Research Ethics Committee approved informed consent, and have met all of the protocol eligibility criteria will continue receiving daily oral entecavir (0.5-1.0 mg/day) or daily oral tenofovir (300 mg/day) and a single IV injection of ARC-520. If a serious adverse event (SAE) deemed possibly or probably related to study drug should occur at any point during the study, any further dosing will be put on hold pending a complete review of safety data by the sponsor and the Principal Investigator. Patients will undergo the following evaluations at regular intervals during the study: medical history, physical examinations, vital sign measurements (blood pressure, heart rate, respiratory rate, and temperature), weight, AEs, 12-lead ECGs, concomitant medication, blood sample collection for hematology, coagulation, chemistry, PK and exploratory PD measures, HBV virology. Patients will be monitored for a total of 12 weeks. Clinically significant changes including AEs will be followed until resolution, until the condition stabilizes, until the event is otherwise explained, or until the patient is lost to follow-up.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date March 2016
Est. primary completion date December 2015
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Male or female, 18 to 65 years of age

- Written informed consent

- No clinically significant abnormalities at screening/pre-dose 12-lead ECG assessment

- No abnormal finding of clinical relevance

- Diagnosis of immune active chronic HBV infection

- > 6 months of continuous treatment with daily, oral entecavir or tenofovir

Exclusion Criteria:

- Pregnant or lactating

- Acute signs of hepatitis/other infection within 4 weeks of screening

- Antiviral therapy other than entecavir or tenofovir within 3 months of screening

- Prior treatment with interferon or a toll receptor agonist in last 12 months

- Use of anticoagulants, corticosteroids, immunomodulators, or immunosuppressants

- Use of dietary and/or herbal supplements that can interfere with liver metabolism

- Use of any drugs known to induce or inhibit hepatic drug metabolism

- Use of prescription medication or over-the-counter products

- Depot injection/implant of any drug except birth control.

- Known diagnosis of diabetes mellitus.

- History of autoimmune disease

- Human immunodeficiency virus (HIV) infection

- Sero-positive for HCV, and/or history of delta virus hepatitis

- Hypertension: blood pressure > 150/100 mmHg

- History of cardiac rhythm disturbances

- Family history of congenital long QT syndrome/unexplained sudden cardiac death

- Symptomatic heart failure, unstable angina, myocardial infarction, severe cardiovascular disease

- History of malignancy, except adequately treated basal cell carcinoma, squamous cell skin cancer, superficial bladder tumors, in situ cervical cancer

- Major surgery within 3 months of screening

- History of alcohol and/or drug abuse < 12 months from screening

- Regularly uses alcohol within past 6 months (ie, more than 14 units of alcohol per week)

- Evidence of acute inflammation, sepsis, or hemolysis

- Diagnosed with a significant psychiatric disorder

- Use of drugs of abuse

- History of allergy to bee venom

- Use of investigational agents/devices within 30 days

- Current participation in an investigational study

- Clinically significant gastrointestinal pathology, unresolved gastrointestinal symptoms, liver or kidney disease

- History/presence of Gilbert's syndrome, conditions that interfere with absorption, distribution, metabolism, excretion of drugs

- Presence of cholangitis, cholecystitis, cholestasis, or duct obstruction

- Clinically significant history/presence of uncontrolled systemic disease

- Donated blood (500 mL) within 7 days prior to study treatment administration

- History of fever within 2 weeks of screening

- Immunization/planned immunization with live attenuated vaccine except influenza vaccine

- Excessive exercise/physical activity within 7 days of screening/enrolment or during study

- History of coagulopathy or stroke within past 6 months, and/or concurrent anticoagulants

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
ARC-520 Injection
ARC-520 Injection is a liver-targeted antiviral therapeutic designed to treat chronic hepatitis B virus (HBV) infection via an RNA interference (RNAi) mechanism.

Locations

Country Name City State
Australia Nucleus Network Ltd Melbourne Victoria

Sponsors (1)

Lead Sponsor Collaborator
Arrowhead Research Corporation

Country where clinical trial is conducted

Australia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Efficacy: To evaluate the depth and duration of HBsAg decline in response to a single dose of ARC 520 in combination with entecavir or tenofovir in patients with chronic HBV infection Through Day 85 post-dosing No
Secondary Safety:To determine the safety and tolerability of ARC 520 through monitoring of adverse events, vital signs, physical exam changes, blood sampling for hematology, coagulation and chemistry and 12-lead ECGs Through Day 85 post-dosing Yes
Secondary Pharmacokinetic parameters: Cmax, AUC0-24, AUClast, AUCinf, CL, V=CL/kel, kel, t1/2 Blood samples collected immediately prior to infusion and immediately prior to end of infusion, and 0.5,1,3,6,24,48 hrs post-infusion. Post dosing on Days 1,2 & 3 No
Secondary Allergenicity:Evaluate Allergenicity of ARC-520 through Bee Venom Allergy Test (IgE) Within 30 days prior to first dose and at Day 29 Yes
See also
  Status Clinical Trial Phase
Recruiting NCT04496882 - Chronic Hepatitis b Patients Switch to tAf After Discontinuation of Nucleoside Analogue Phase 4
Completed NCT04083716 - A Study to Assess the Relative Bioavailability and Food Effect of ABI-H2158 in Healthy Adults Phase 1
Not yet recruiting NCT03038802 - A Randomised Controlled Phase 1 Study of Vaccine Therapy for Control or Cure of Chronic Hepatitis B Virus Infection Phase 1/Phase 2
Completed NCT05310487 - Phase 1 Study of 162, a Novel Neutralizing Antibody Targeting Hepatitis B Surface Antigen, in Healthy Adult Subjects Phase 1
Recruiting NCT06070051 - Dose-Escalation Prime/Boost Therapeutic Vaccination Study Of 2 Chimp Adenoviral Vectors in Adults With Chronic HBV On Nucleos(t)Ide Therapy Phase 1
Terminated NCT05001022 - A Study of ALG-020572 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single Doses in Healthy Volunteers and Multiple Doses in CHB Subjects Phase 1
Recruiting NCT04139850 - The Establishment of Korean Hepatitis B Patients Cohort
Recruiting NCT05343481 - Efficacy of VTP-300 in Chronic Hepatitis B Infection Phase 2
Not yet recruiting NCT05490836 - Functional Cure Rate of Peg-IFNα-2b Combined With TAF in HBeAg Negative CHB Patients N/A
Recruiting NCT04543565 - Pradefovir Treatment for the Patients With Chronic Hepatitis B Virus Infections: a Phase3 Study Phase 3
Active, not recruiting NCT02894918 - A Study to Evaluate Addition of Peginterferon Alfa-2a to Chronic Hepatitis B (CHB) Patients Treated With NAs Phase 4
Not yet recruiting NCT02793791 - Prophylactic Treatment of Hepatic Dysplastic Nodules in HBsAg Positive Patients N/A
Recruiting NCT02287857 - Efficacy and Safety of Domestic Tenofovir Tablets in Chinese Patients With Chronic Hepatitis B N/A
Recruiting NCT01965418 - A Clinical Evaluation on Traditional Chinese Medicine Diagnosis and Treatment Program Blocking and Reversing Hepatitis B-related Liver Fibrosis - a Randomized, Controlled, Double-blind, Multi-center Clinical Trial Phase 4
Recruiting NCT01491295 - Switch to Tenofovir Versus Continue Lamivudine/Adefovir Treatment in Lamivudine-resistance Chronic Hepatitis B Patients Phase 4
Terminated NCT01872988 - Tenofovir Antiviral Therapy Following Transarterial Chemoembolization for HBV Related Hepatocellular Carcinoma Phase 3
Recruiting NCT01487876 - Efficacy and Safety of Dual-plasmid Hepatitis B Virus DNA Vaccine in Chronic Hepatitis B Patients Phase 2
Not yet recruiting NCT01436539 - Study of Effects and Safety Between Adefovir Dipivoxil Plus Polyene Phosphatidylcholine Versus Adefovir Dipivoxil Alone in Chronic Hepatitis B Patients Phase 4
Completed NCT01531166 - A Cohort Study in Korean Patients With Chronic Hepatitis B (CHB) Receiving Pegylated Interferon N/A
Recruiting NCT01360879 - Assessment of Liver FIBROsis by Real-time Tissue ELASTography in Chronic Liver Disease N/A